HEPATITIS B TREATMENT VACCINE ON THE BASIS OF INACTIVATED, FULLY RECOMBINANT HANSENULA CELLS EXPRESSING HBSAG

摘要

A hepatitis B treatment vaccine on the basis of inactivated, recombinant Hansenula cells expressing HBsAg. The vaccine is the HBsAg expressed in recombinant Hansenula cells. 10⁸ cells contain 6-10µg HBsAg as an antigen; the vaccine contains a total of 16-21 HBsAg-specific CTL epitopes; the vaccine uses optimized inactivated, fully recombinant Hansenula cells as an adjuvant.